Prescribing information (external link)
LEQVIO® (inclisiran) is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:1
in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach low-density lipoprotein cholesterol (LDL-C) goals with the maximum tolerated dose of a statin, or
alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated
For full safety information, please refer to the LEQVIO® Summary of Product Characteristics (SmPC).
LEQVIO® dosing and administration
With twice-yearly dosing, LEQVIO® can be administered during existing patient appointments*1
The recommended dose of LEQVIO® is 284 mg, administered subcutaneously via a single pre-filled syringe: initially, again at 3 months and thereafter every 6 months.1
Your guide to using LEQVIO®
LEQVIO dosing and administration: ‘How to’ guide
This resource is designed to give you an overview of LEQVIO® dosing and administration.
Additional dosing and administration information
LEQVIO® is administered subcutaneously by a healthcare professional into the abdomen, upper arm or thigh (avoid active skin disease or injury, e.g., sunburns, skin rashes, inflammation, skin infections).1
No dose adjustments are required with LEQVIO®, including patients with mild or moderate hepatic impairment, mild, moderate or severe renal impairment or end-stage renal disease, or elderly patients (age ≥65 years). No additional blood monitoring is mandated with LEQVIO®.† There is no requirement to refrigerate LEQVIO®. LEQVIO® should be used with caution in patients with severe hepatic impairment or severe renal impairment. No data are available for these patients.1
If LEQVIO® should be inspected visually prior to administration. The solution should be clear, colourless to pale yellow and essentially free of particulates. If the solution contains visible particulate matter, the solution should not be used. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.1
If a planned dose is missed by less than 3 months, LEQVIO® should be administered and dosing continued according to the patient's original schedule. If a planned dose is missed by more than 3 months, a new dosing schedule should be started – LEQVIO® should be administered initially, again at 3 months, followed by every 6 months.1
For further information, please refer to the SmPC.
Dosing in special populations
Elderly (age ≥65 years)
No dose adjustment1
Hepatic impairment
No dose adjustment: mild (Child-Pugh class A) or moderate (Child-Pugh class B)1
Use with caution as no data available: severe (Child-Pugh class C)1
Renal impairment
No dose adjustment: mild, moderate or severe, or end-stage renal disease1
Use with caution due to limited experience: severe1
Haemodialysis should not be performed for at least 72 hours after LEQVIO® dosing1
Pregnancy/breastfeeding
Avoid use during pregnancy as no data available1
Decide whether to discontinue breastfeeding or to discontinue/abstain from LEQVIO® as a risk to newborns/infants cannot be excluded1
For further information, please refer to the SmPC.
Access more resources for LEQVIO®
*After an initial dose, LEQVIO® is administered again at 3 months, followed by every 6 months.1
†Beyond what is already clinically indicated.1
LDL-C, low-density lipoprotein cholesterol; SmPC, summary of product characteristics.
Reference
LEQVIO® Summary of Product Characteristics.
LEQVIO® and the LEQVIO® logo are registered trademarks of Novartis AG. Licensed from Alnylam Pharmaceuticals, Inc.
UK | May 2026 | FA-11570721
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
